Cardiovascular Diseases, Cognition Disorder, Cognitive Impairment, Diabetes Mellitus, Type 2, Diastolic Dysfunction, Dietary Habits, Hypertension, Hypertensive Heart Disease, Inflammation, Ischemic Heart Disease, Metabolic Syndrome, Myocardial Infarction, Obesity, Quality of Life
Conditions
Keywords
Spermidine, Dietary supplement, Polyamine, Prevention, Treatment, Lifestyle, Coronary artery disease, Ischemic heart disease, Cardiovascular disease, Heart disease, Hypertension, Obesity, Diabetes Mellitus, Type 2, Insulin resistance, Inflammation, Quality of life, Cognitive function, Memory, Autophagy
Brief summary
The present study is testing spermidine treatment in elderly patients with coronary artery disease. The study is a randomized, double-blind, placebo-controlled, two-armed, parallel-group, single centre, clinical study.
Detailed description
Life expectancy has increased tremendously over the past century and as populations age, chronic diseases such as cardiovascular disease and diabetes have become more prevalent. Healthy aging is therefore of paramount importance to further promote longevity and quality of life. In humans, a high concentration of whole-blood spermidine is associated with longevity, and individuals with a high dietary spermidine intake have improved cardiovascular health and less obesity. Spermidine is essentially a polyamine found in all plant-derived foods, particularly in whole grains, soybeans, nuts, and fruit. Its favorable effects may act via several mechanisms. In an experimental model of hypertensive heart disease, spermidine reduced cardiac hypertrophy and improved diastolic and mitochondrial function. Spermidine also induces cytoprotective autophagy in skeletal muscle and alters body fat accumulation by metabolically modulating glucose and lipid metabolism. The clinical data on spermidine dietary supplementation are scarce. In elderly subjects with cognitive problems, spermidine supplement was well tolerated and had potential blood-pressure-lowering effects. The reported beneficial effects of spermidine raise the question whether elderly patients with cardiovascular disease can benefit from a dietary supplement of this polyamine. The central hypothesis of the current proposal is that a twelve-month spermidine treatment regimen in elderly patients with cardiovascular disease will yield positive effects on heart and skeletal muscle function, whole body composition and inflammation. The secondary hypotheses are that spermidine reduces blood pressure and has a beneficial impact on cognitive function, daily activity level, quality of life, biomarker risk profile, skeletal muscle cellular metabolism and lastly but not least gut microbiota. The study design is a randomized, double-blind, placebo-controlled trial to investigate the effects of a 24 mg daily oral spermidine dietary supplement vs. matching placebo in elderly patients with cardiovascular disease. A total of 200 patients will be included and randomized 1:1 to either spermidine 24 mg x 1 daily or matching placebo for one year. At baseline and after one year of intervention the patients will undergo study procedures. Changes from baseline to follow-up will be compared between the active and placebo treated patient groups.
Interventions
DIETARY_SUPPLEMENTSpermidine
Spermidine capsule of 8 mg x 3 capsules daily.
OTHERPlacebo
Placebo capsule. 3 capsules daily.
Sponsors
University of Aarhus
Sygesikringen Danmark
Aarhus University Hospital
Danish Diabetes Academy
Danish Cardiovascular Academy (DCA)
Eva and Henry Frænkels Mindefond
DoNotAge.org
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Double (Participant, Investigator)
Intervention model description
Randomized, double-blind, placebo-controlled, two-armed, parallel-group, single centre, clinical study.
Eligibility
Sex/Gender
ALL
Age
65 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥ 65 years * Chronic ischemic heart disease (previous revascularization or myocardial infarction) * Left ventricular ejection fraction of \> 40% And at least two of the following risk factors: * Type 2 diabetes, * Obesity (BMI ≥ 30 kg/m2), * Hypertension, * Previous LVEF \< 40%, * Left atrial volume index ≥ 30 mL/m2 * Left ventricular wall thickness ≥ 1.1 cm.
Exclusion criteria
* Unstable coronary syndrome * Significant and severe cardiac valve disease * Severe peripheral artery disease * Permanent atrial fibrillation * Pacemaker treatment * Chronic kidney disease with eGFR \<45 ml/min/1,73m2 * Severe comorbidity as judged by the investigator (such as severe pulmonary, neurological, or musculoskeletal disease) * Inability to give informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in appendicular lean mass and ALM index | From randomization (month 0) to 12 months | Appendicular lean mass and ALM index (Appendicular lean mass/height\^2). Measured by a whole-body dual-energy X ray absorptiometry (DXA) scan. |
| Change in High-sensitivity C-reactive Protein (hs-CRP) | From randomization (month 0) to 12 months | Measured from blood samples. |
| Change in Physical performance, peak oxygen consumption (VO2max) | From randomization (month 0) to 12 months | Measured by cardiopulmonary exercise capacity (CPET) will be performed using a cycle ergometer test. Peak oxygen uptake measured in ml O2/kg/min. |
| Change in left ventricular mass | From randomization (month 0) to 12 months | Measured with Cardiac Magnetic Resonance Imaging (CMR). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in myocardial strain | From randomization (month 0) to 12 months | Assessed using Cardiac Magnetic Resonance Imaging (CMR) with intravenous gadolinium-based agent. |
| Change in Carotid-femoral pulse wave velocity | From randomization (month 0) to 12 months | Measured non-invasively through applanation tonometry using a SphygmoCor system. The unit of measure is m/s. |
| Change in Aortic pulse wave velocity | From randomization (month 0) to 12 months | Magnetic resonance imaging (MRI) assessment. The unit of measure is m/s. |
| Change in general cognitive function and memory performance | From randomization (month 0) to 12 months | Evaluated using the Montreal Cognitive Assessment (MoCA). It will be administered in a clinical setting using a tablet. MoCA score ranges from 0-30 and a score of 26 or higher is considered normal. |
| Change in specific domains of cognitive function | From randomization (month 0) to 12 months | Evaluated using Cambridge Cognition (CANTAB) digital assessment software in a clinical setting using a tablet. The cognitive tests are MOT, RTI, SWM, DMS and PAL. These tests will objectively measure psychomotor speed, executive function and memory. |
| HeartQol | From randomization (month 0) to 12 months | HeartQol measures health-related quality of life (HRQL) and is a disease-specific health status instrument for ischemic heart disease. It consists of 14 items and provides two subscales; a 10-item physical subscale and a 4-item emotional subscale, which are scored on a four-point Likert scale (0 to 3). Higher scores indicate a better HRQL. Measured as global, physical and emotional score. |
| Cytokines | From randomization (month 0) to 12 months | Changes in cytokines are evaluated through the utilization of multiplex cytokine assays. Measured from plasma blood samples. |
| White blood cells | From randomization (month 0) to 12 months | Changes in white blood cell differential count. |
| Immune cells | From randomization (month 0) to 12 months | Changes in specific immune cell populations are measured using peripheral blood mononuclear cells (PBMCs) isolated from blood samples. |
| Vascular inflammatory markers | From randomization (month 0) to 12 months | Measured from plasma blood samples with a multiplex assay. |
| Time to first occurrence of Composite cardiovascular endpoint: Cardiovascular death, heart failure hospitalizations, non-fatal myocardial infarction, non-fatal stroke, and coronary revascularization | From randomization (month 0) to 12 months | Measured in months. |
| Days alive and out of hospital | From randomization (month 0) to 12 months | Measured in months. |
| Polyamine content in muscle biopsy | From randomization (month 0) to 12 months | Measured with liquid chromatography mass spectrometry (LC-MS). |
| Polyamine content in blood | From randomization (month 0) to 12 months | Plasma samples obtained from blood. Measured with liquid chromatography mass spectrometry (LC-MS). |
| Muscle strength, Handgrip strength | From randomization (month 0) to 12 months | Hand-held dynamometer for measuring handgrip strength in kilograms. |
| Muscle strength, Knee-extension/flexion strength | From randomization (month 0) to 12 months | Change in knee extension and flexion isokinetic strength (assessed by peak torque, Nm) and isometric strength (assessed by peak torque, Nm). |
| Physical performance, 6 minute walk test (6MWT) | From randomization (month 0) to 12 months | Change in walking distance in meters. |
| Physical performance, 30 seconds sit to stand test | From randomization (month 0) to 12 months | Change in counts of sit to stand. |
| The Short Physical Performance Battery | From randomization (month 0) to 12 months | Changes in points. |
| Skeletal muscle mass | From randomization (month 0) to 12 months | Thigh muscle mass by Magnetic Resonance Imaging (MRI) using Dixon method. |
| Skeletal muscle cross sectional area (CSA) of fibers | From randomization (month 0) to 12 months | CSA of fibers by cryosection of skeletal muscle biopsy obtained from vastus lateralis muscle. |
| Skeletal muscle tissue fiber composition | From randomization (month 0) to 12 months | Change in ratio between muscle fiber types (type I, IIa and IIb) assessed by immunohistochemistry. |
| Skeletal muscle tissue cellular composition | From randomization (month 0) to 12 months | Change in muscle tissue cellular composition assessed by cell sorting |
| Skeletal muscle mitochondrial function | From randomization (month 0) to 12 months | Change in muscle mitochondrial function assessed by high-resolution respirometry |
| Total lean body mass | From randomization (month 0) to 12 months | Change in lean body mass (in grams) and total lean mass/height\^2. |
| Total body fat percentage | From randomization (month 0) to 12 months | Changes in body fat percentage. |
| Estimated visceral adipose tissue | From randomization (month 0) to 12 months | Change in VAT index (kilogram-per-meters-squared index) and in mass (in grams). |
| Intramuscular and intermuscular fat content | From randomization (month 0) to 12 months | Calculating thigh adipose tissue mass located between and within muscle fibers by MRI Dixon method. |
| Free fatty acids | From randomization (month 0) to 12 months | Measured from blood samples. |
| Insulin resistance | From randomization (month 0) to 12 months | Changes in insulin resistance assessed by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). |
| Change in 24-hour ambulatory blood pressure measurements (24h ABPM) | From randomization (month 0) to 12 months | Measured with the Spacelabs Healthcare 90217A device in an out-of-hospital setting. |
| Markers of autophagy | From randomization (month 0) to 12 months | Proteomics of skeletal muscle tissue and peripheral blood mononuclear cells (PBMCs). |
| Change in central blood pressure | From randomization (month 0) to 12 months | Measured noninvasive with pulse wave analysis (PWA) using a SphygmoCor system. |
| Change in daily physical activity | From randomization (month 0) to 12 months | Assessed by 14-day activity monitoring with an accelerometer (AX3, Axivity). |
| Change in cardiac extracellular volume fraction | From randomization (month 0) to 12 months | Assessed using Cardiac Magnetic Resonance Imaging (CMR) with intravenous gadolinium-based agent. |
Countries
Denmark
Contacts
PRINCIPAL_INVESTIGATORHenrik Wiggers, DMSC PHD MD
Dept. of Cardiology, Aarhus University Hospital
Outcome results
None listed